ADAMTS13对急性缺血性卒中再通治疗反应预测的价值
研究纳入108例接受静脉tPA治疗的急性缺血性卒中动脉闭塞患者,基线ADAMTS13活性>75%独立预测再通(OR=6.76)。78例接受血管内取栓患者中,ADAMTS13浓度<982 ng/mL独立预测无效再通(OR=67.4)。加入ADAMTS13可改善预测判别与重分类。
要点
- tPA再通患者基线ADAMTS13活性高于未再通者(78.1% vs 70.1%,p=0.021)。
核心结论
- ADAMTS13降低与再通治疗反应差相关;若未来前瞻性研究证实,包含ADAMTS13的血液生物标志物组合可能有助于指导再灌注治疗。
研究设计与样本
- 研究纳入108例经静脉tPA治疗且有动脉闭塞记录的急性缺血性卒中患者,治疗前采血以ELISA测ADAMTS13活性,2小时后经颅多普勒评估再通。
- 另纳入78例连续接受血管内取栓的患者,以ELISA测ADAMTS13抗原,无效再通定义为完全再通且3个月改良Rankin量表评分>2。
- 采用logistic回归分析再通与无效再通的独立预测因素,校正年龄、NIH卒中量表评分和卒中发作至治疗时间。
主要发现
- 实现tPA诱导再通的患者基线ADAMTS13活性较高(78.1%[68%-88%] vs 70.1%[61%-79%],p=0.021)。
- ADAMTS13活性>75%是再通的独立预测因素(OR=6.76[1.52-30.02],p=0.012), junto with 无早期缺血征象和牛津郡社区卒中项目分类。
- 血管内治疗中,ADAMTS13浓度降低(<982 ng/mL)是无效再通的独立预测因素(OR=67.4[1.4-3,282.1],p=0.034), junto with 年龄和糖尿病。
- 将ADAMTS13加入tPA再通和无效再通的临床预测因素后,判别与重分类改善(integrated discrimination improvement分别为10.06%和28.4%,net reclassification improvement分别为61.0%和107.4%)。
临床怎么用
- 作者认为若未来前瞻性研究证实,包含ADAMTS13的血液生物标志物组合可能有助于指导再灌注治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: We aimed to analyze ADAMTS13 (a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13) in relation to arterial recanalization in patients treated with IV tissue plasminogen activator (tPA) and in relation to futile recanalization in patients treated with mechanical thrombectomy. METHODS: Acute ischemic stroke patients (n = 108) with documented arterial occlusions treated with IV-tPA were selected. ADAMTS13 activity was measured by ELISA in samples collected before treatment. Recanalization was assessed at 2 hours by transcranial Doppler. In 78 consecutive patients treated with endovascular thrombectomy, ADAMTS13 antigen was measured by ELISA and futile recanalization was defined as complete recanalization plus modified Rankin Scale score >2 at 3 months. Independent predictors of recanalization and futile recanalization were determined by logistic regression, adjusted by age, NIH Stroke Scale score, and time from stroke onset. RESULTS: Patients who achieved tPA-induced recanalization had higher baseline ADAMTS13 activity (78.1% [68%-88%] vs 70.1% [61%-79%], p = 0.021). In logistic regression analysis, ADAMTS13 activity >75% was an independent predictor of recanalization (odds ratio = 6.76 [1.52-30.02], p = 0.012), together with absence of early ischemic signs and Oxfordshire Community Stroke Project classification. Regarding endovascular therapies, a reduced ADAMTS13 concentration (<982 ng/mL) was an independent predictor of futile recanalization (odds ratio = 67.4 [1.4-3,282.1], p = 0.034), together with age and diabetes mellitus. The addition of ADAMTS13 to clinical predictors of tPA-induced recanalization and futile recanalization improved discrimination and reclassification (integrated discrimination improvement = 10.06% and 28.4%, net reclassification improvement = 61.0% and 107.4%, respectively). CONCLUSIONS: A reduced ADAMTS13 was associated with poor response to recanalization therapies. If confirmed in future prospective studies, a panel of blood biomarkers including ADAMTS13 might be a useful tool to guide reperfusion therapies.
引用
- Bustamante A, Ning M, García-Berrocoso T, et al. Usefulness of ADAMTS13 to predict response to recanalization therapies in acute ischemic stroke. Neurology. 2018. PMID: 29444972. doi:10.1212/WNL.0000000000005162
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。